旨在评估乳腺癌化疗治疗前控制性卵巢刺激用于保留生育能力的长期安全性设计：回顾性观察队列受试者：2015 年期间接受全身化疗的 213 名 18-43 岁新诊断 I-III 期乳腺癌女性患者2019.其中，74 名接受受控卵巢刺激以保留生育能力的受者，141 名没有接受受控卵巢刺激（对照组）。 受控卵巢刺激以保留生育能力 主要观察指标： 无侵袭性生存期，从手术时间到检测出乳腺癌时计算复发或死亡，以先发生者为准。 诊断时，生育力保留接受者明显比对照组年轻（32.7 岁 vs 38.5 岁），婚配（44.4% vs 90.1%）或经产（38.9% vs 95%）的可能性较小，并且更有可能携带 BRCA 种系突变（36.5% vs 14.2%）。除肿瘤分期外，各组之间的疾病特征和治疗方式具有可比性，生育力保留受者中 22.2% 的最大肿瘤直径超过 5 cm，而对照组为 5.7%（P<0.05）。生育力保存受者和对照者的平均随访时间分别为 60.9 个月和 65.4 个月。生育力保留受者的 5 年无侵袭性疾病生存率为 80%，对照组为 86%（p=0.20）。在针对统计显着协变量进行调整的多变量分析中，各组之间的无侵袭性疾病生存率保持相似（风险比 (HR)，0.86，95CI 0.4-1.87，p = 0.71）。在临床相关亚组中，包括接受新辅助化疗的患者（HR 1.57，CI 95 0.62-3.99，p = 0.34）以及因 ER 阳性疾病而在刺激期间与他莫昔芬联合治疗的患者，无侵袭性疾病生存率没​​有统计学差异（ HR 1.66，95CI 0.67-3.49，p=0.23)。未发现乳腺癌患者通过受控卵巢刺激保留生育能力会损害长期肿瘤学结果，包括新兴的临床相关亚组。版权所有 © 2024。由 Elsevier Inc 出版。

To evaluate the long-term safety of controlled ovarian stimulation for fertility preservation prior to breast cancer chemotherapy treatment DESIGN: Retrospective observational cohort SUBJECTS: 213 women aged 18-43 years with newly diagnosed stage I-III breast cancer treated with systemic chemotherapy during 2015-2019. Of those, 74 underwent controlled ovarian stimulation for fertility preservation recipients and 141 did not (controls).Controlled ovarian stimulation for fertility preservation MAIN OUTCOME MEASURES: Invasive disease-free survival, calculated from the time of surgery to the time of detection of breast cancer recurrence or death, whichever came first.At diagnosis, fertility preservation recipients were significantly younger than controls (32.7 vs 38.5 years), were less likely to be partnered (44.4% vs 90.1%) or parous (38.9% vs 95%) and were more likely to harbor a BRCA germline mutation (36.5% vs 14.2%). Disease characteristics and treatment modalities were comparable between groups, apart from tumor staging, with maximal tumor diameter being over 5 cm in 22.2% of fertility preservation recipients as opposed to 5.7% of controls (P<0.05). Mean follow-up was 60.9 and 65.4 months for fertility preservation recipients and controls, respectively. 5-year-invasive disease free survival was 80% for fertility preservation recipients and 86% for controls (p=0.20). In a multivariate analysis adjusted for statistically significant covariates, invasive disease free survival remained similar between the groups (Hazards Ratio (HR), 0.86, 95CI 0.4-1.87, p = 0.71). Invasive disease free survival rates were not statistically different in clinically relevant subgroups including patients receiving neoadjuvant chemotherapy (HR 1.57, CI 95 0.62-3.99, p=0.34), and those co-treated with tamoxifen during stimulation due to an ER-positive disease (HR 1.66, 95CI 0.67-3.49, p=0.23).Fertility preservation with controlled ovarian stimulation for patients with breast cancer was not found to impair long-term oncologic outcomes, including in emerging clinically relevant subgroups.Copyright © 2024. Published by Elsevier Inc.